Ono Pharmaceutical Co., Ltd.

AROCYTE

Pharmaceutical drugs and medicines for treatment of diseases of the central nervous system and diseases of the circulatory system;

AROCYTE

Pharmaceutical drugs and medicines for treatment of diseases of the central nervous system and diseases of the circulatory system;

CEREACT

pharmaceutical drugs and medicines for treatment of neurologic disorders;

ELASPOL

Pharmaceuticals for treating problems from the over-production of the enzyme elastase;

ELASPOL

pharmaceuticals for treating problems from the over-production of the enzyme elastase; diagnostic preparations for clinical or medical laboratory use;

FOY

In the heading, Int. Cl.: 10 and Prior U.S. Cl.: 44 should be deleted and Int. Cl.: 5 and Prior U.S. Cl.: 18 should be inserted. In the statement, column 2, line 7, Class 10 (U.S. Cl. 44) should be deleted and Class 5 (U.S. Cl. 18) should be inserted.;Pharmaceutical Medicines and Drugs for U;Pharmaceutical Medicines and Drugs for Use in the Treatment and Prevention of Pancreatitis, Shock, Rheumatoid Arthritis, Thrombosis and Disseminated Intravascular Coagulation and Anti-Coagulants;

ONO

Medical testing services and medical research for all pharmaceuticals and medicines;

ONO

The stylized word mark ONO inside a black square.;Color is not claimed as a feature of the mark.;Medical testing services;Medical research for all pharmaceuticals and medicines;

ONO

The mark consists of the stylized word ONO in the color white, inside a black square.;venture capital financing; venture capital fund management; venture capital advisory services; providing venture capital, development capital, private equity and investment funding; venture capital funding services to emerging and start-up companies; venture capital services, namely, providing financing to emerging and start-up companies;The color(s) white and black is/are claimed as a feature of the mark.;